Biosimilars Transform Psoriasis & PsA Treatment: Affordable, Effective Alternatives
Biosimilars, copies of existing biological medicines, are playing a significant role in treating psoriasis and psoriatic arthritis, offering cost savings and increased availability. These biological drugs target specific areas of the immune system, blocking inflammatory proteins that cause disease symptoms. However, biologics can be expensive, with annual costs ranging from $10,000 to $30,000, and sometimes exceeding $500,000 for the most expensive ones. Biosimilars, being as safe and effective as biologics, provide a more affordable alternative to treat psoriatic arthritis.
Biosimilars are manufactured by various companies, with some of the most common being Pfizer, Merck & Co., Samsung Bioepis, Sandoz, Amgen, Boehringer Ingelheim, and Celltrion. These manufacturers produce biosimilars for popular biologics like Infliximab, Etanercept, Adalimumab, Golimumab, and Ustekinumab, which are commonly used to treat psoriatic arthritis. Symptoms of psoriatic arthritis include joint pain, swelling, and redness. Biologics and biosimilars are typically administered by injection or IV infusion and are recommended as first-line treatments due to their effectiveness. Doctors can help determine if these treatments are accessible and suitable for individual patients. Insurance coverage and availability also impact the out-of-pocket costs of these medications. It's worth noting that some people with psoriasis may also develop psoriatic arthritis, a chronic inflammatory arthritis affecting major joints like knees and hips.
Biosimilars, with their reduced costs due to streamlined research, development, and testing, are increasingly important in treating psoriatic arthritis. They offer patients and healthcare systems a more affordable alternative to biologics, expanding treatment options and potentially improving access to these life-changing medications.
